Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes
ACTON, Mass.--(BUSINESS WIRE)--
an emerging medical device company, will present clinical data in a
poster session on Wednesday, July 17, 11:45 a.m.2:15 p.m. EDT, at the that its
eye test identified Alzheimers disease patients via a
(Ab) signature in their eyes in a 10-subject proof-of-concept clinical
trial. By detecting a specific fluorescent signature of ligand-marked in the supranucleus region of the human lens,
achieved a factor between a group of five
healthy volunteers and a group of five patients diagnosed with probable
HERE FOR A SCIENTIFIC PRESENTATION ABOUT THE COGNOPTIX EYE TEST FOR AD.)
There is a significant effort underway in the scientific and medical
communities that is investigating the function of
neuritic plaques in the brains of adult patients with cognitive
impairment and possible Alzheimers disease, said ,
F.A.A.N., Medical Director at Premiere Research Institute in West Palm
Beach Fla., and a principal investigator in the SAPPHIRE clinical study.
While it is true that Positron Emission Tomography (PET) imaging has
been approved to enable detection of neuritic
plaques in AD patients, there is, nevertheless, a dire
need for a low cost, noninvasive technology capable of upgrading the
differential diagnosis of dementia, which would be extremely practical
for widespread use at the point-of-care.
There currently is no early-stage noninvasive test for Alzheimers
disease, added , President and CEO of Cognoptix.
This is unfortunate, given that patients often incur as much as 50%
neuronal loss and a delay of up to two years
severe enough symptoms to achieve diagnosis of AD by the current gold
standard: which is a process of elimination of other possible diagnoses
such as stroke, trauma, Parkinsons disease and dementia, through a
battery of cognitive and physical testing. On the other hand, new
therapeutic drugs to slow or stop the progress of AD are expected to
reach the market soon. Cognoptix is developing a method of early-stage
diagnosis to allow treatment significant neuronal loss and
irreversible brain damage occurs.
There are nearly 100 new Alzheimers drugs that are in various stages of
research and development. The ability of the Cognoptix drug/device
combination to easily identify and qualify patients for clinical study
inclusion, as well as accurately and inexpensively track patient disease
progression, may provide pharmaceutical companies with a significant
competitive advantage in securing new Alzheimers drug approvals. It may
also help identify and document differentiating pharmaceutical product
performance attributes in Phase 4 studies.
Cognoptix has developed an in-office,
drug/device diagnostic system designed as an aid in the early detection
of Alzheimers Disease (AD) pathology. A ligand or contrast agent (drug)
and software-controlled optical instrument (device) allows for
noninvasive detection and assessment of AD by measuring the hallmark of
AD, , in the supranuclear region of the lens of the
eye. The ligand is easily administered to the eye as an ophthalmic
ointment and a proprietary Fluorescent Ligand Scanning (FLS) instrument,
provides an objective and quantitative measurement of beta amyloid in
the patients lens. Significantly faster and an order of magnitude less
expensive than brain imaging, the test and diagnosis can be quickly
completed in any physicians office, including general practitioners.
The technology is currently in clinical trials. Cognoptix has a strong
and comprehensive patent portfolio covering diagnosis of beta
amyloid-based diseases via ophthalmic imaging. The patent portfolio
includes issued method and device patents, as well as pending
composition of matter patents. In addition to UC San Diego, exclusive
licenses have been acquired from Massachusetts General Hospital and
Brigham and Womens Hospital Boston.
Cognoptix, a privately held medical
technology company headquartered in Acton, Mass., is focused on
developing and commercializing an in-office, drug/device diagnostic
system as an aid in the early detection of Alzheimers Disease (AD). Its
investors include , one of the worlds
largest life sciences-, nutrition- and wellness-focused venture capital
firms; and , a Boston-based angel
investment firm that provides funding to early-stage companies.
NOTE: The SAPPHIRE II system is approved for investigational use only in
the United States.
Ronald Trahan Associates Inc.Ronald Trahan, APR, +1-508-359-4005,